SYS-6010
- Generic Name
- SYS-6010
A Study of SYS6010 and Platinum-based Chemotherapy in Patients With EGFR-mutated NSCLC.
Phase 3
Not yet recruiting
- Conditions
- EGFR-mutated Locally Advanced or Metastatic NSCLC
- Interventions
- First Posted Date
- 2025-04-15
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
- Target Recruit Count
- 380
- Registration Number
- NCT06927986
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
- First Posted Date
- 2023-07-17
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Conjupro Biotherapeutics, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT05948865
- Locations
- 🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇺🇸USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸UCLA Hematology/Oncology - Santa Monica, Santa Monica, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath